Lyell Immunopharma Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
161
- Stock Symbol
-
LYEL
- Investments
-
8
- Share Price
-
$14.62
- (As of Monday Closing)
Lyell Immunopharma General Information
Description
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Contact Information
Website
www.lyell.comCorporate Office
- 201 Haskins Way
- Suite 101
- South San Francisco, CA 94080
- United States
Corporate Office
- 201 Haskins Way
- Suite 101
- South San Francisco, CA 94080
- United States
Lyell Immunopharma Stock Performance
As of 16-Nov-2026, Lyell Immunopharma’s stock price is $14.62. Its current market cap is $468M with 32M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $14.62 | $14.30 | $7.20 - $45.00 | $468M | 32M | 178K | -$12.61 |
Lyell Immunopharma Financials Summary
As of 30-Sep-2026, Lyell Immunopharma has a trailing 12-month revenue of $15K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 72,737 | 378,550 | (202,123) | (28,229) |
| Revenue | 15 | 36 | 61 | 130 |
| EBITDA | (255,114) | (275,989) | (347,431) | (237,835) |
| Net Income | (255,160) | (274,448) | (342,994) | (234,632) |
| Total Assets | 273,854 | 340,052 | 490,859 | 750,029 |
| Total Debt | 34,315 | 50,994 | 58,968 | 63,167 |
Lyell Immunopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lyell Immunopharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Lyell Immunopharma Comparisons
Industry
Financing
Details
Lyell Immunopharma Competitors (48)
One of Lyell Immunopharma’s 48 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| ORIC Pharmaceuticals | Formerly VC-backed | South San Francisco, CA | ||||
| Kyverna | Formerly VC-backed | Emeryville, CA | ||||
| Instil Bio | Formerly VC-backed | Dallas, TX | ||||
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA |
Lyell Immunopharma Patents
Lyell Immunopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026102456-A1 | Methods of treating cancer by administering bispecific cd19/cd20 car t cells | Pending | 11-Nov-2024 | ||
| WO-2026006604-A1 | Feeder cell replacement | Pending | 26-Jun-2024 | ||
| WO-2025217398-A1 | Methods for culturing cells with improved culture medium | Pending | 10-Apr-2024 | ||
| WO-2025096419-A1 | T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof | Inactive | 31-Oct-2023 | ||
| WO-2025058919-A1 | Bispecific chimeric antigen receptors and use thereof | Inactive | 12-Sep-2023 | C07K16/28 |
Lyell Immunopharma Signals
Lyell Immunopharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lyell Immunopharma Investments & Acquisitions (8)
Lyell Immunopharma’s most recent deal was a Corporate Asset Purchase with Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) for . The deal was made on 10-Nov-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) | 10-Nov-2025 | Corporate Asset Purchase | Buildings and Property | ||
| ImmPACT Bio | 31-Oct-2024 | Merger/Acquisition | Drug Discovery | ||
| Outpace Bio | 03-Feb-2021 | Early Stage VC | Discovery Tools (Healthcare) | ||
| Sonoma Biotherapeutics | 30-Sep-2020 | Early Stage VC | Drug Discovery | ||
| Immulus | 23-May-2020 | Early Stage VC | Biotechnology |
Lyell Immunopharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.64 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Lyell Immunopharma Exits (3)
Lyell Immunopharma’s most recent exit was on 23-May-2020 from Immulus. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Immulus | 23-May-2020 | Completed |
|
||
| PACT Pharma | 10-Jan-2020 | Completed |
|
||
| CERo Therapeutics Holdings | 26-Nov-2019 | Early Stage VC | Completed |
|
Lyell Immunopharma FAQs
-
When was Lyell Immunopharma founded?
Lyell Immunopharma was founded in 2018.
-
Where is Lyell Immunopharma headquartered?
Lyell Immunopharma is headquartered in South San Francisco, CA.
-
What is the size of Lyell Immunopharma?
Lyell Immunopharma has 161 total employees.
-
What industry is Lyell Immunopharma in?
Lyell Immunopharma’s primary industry is Drug Discovery.
-
Is Lyell Immunopharma a private or public company?
Lyell Immunopharma is a Public company.
-
What is Lyell Immunopharma’s stock symbol?
The ticker symbol for Lyell Immunopharma is LYEL.
-
What is the current stock price of Lyell Immunopharma?
As of 16-Nov-2026 the stock price of Lyell Immunopharma is $14.62.
-
What is the current market cap of Lyell Immunopharma?
The current market capitalization of Lyell Immunopharma is $468M.
-
What is Lyell Immunopharma’s current revenue?
The trailing twelve month revenue for Lyell Immunopharma is $15K.
-
Who are Lyell Immunopharma’s competitors?
Aura Biosciences, ORIC Pharmaceuticals, Kyverna, Instil Bio, and Aclaris Therapeutics are some of the 48 competitors of Lyell Immunopharma.
-
What is Lyell Immunopharma’s annual earnings per share (EPS)?
Lyell Immunopharma’s EPS for 12 months was -$12.61.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process